ACVR2A/Activin RIIA 蛋白, Human (HEK293, C-His)

ACVR2A, also known as Activin RIIA, is an activin type II receptor. On ligand binding, ACVR2A can forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. ACVR2A is a receptor for Activin A, Activin B and Inhibin A^[1][2]. ACVR2A/Activin RIIA Protein, Human (HEK293, His) is produced in HEK293 cells with six C-Terminal His-tags. It consists of 115 amino acids (A20-P134).

ACVR2A 是受体丝氨酸/苏氨酸激酶 TGF-β 家族的 II 型成员。ACVR2A 是激活素 A、激活素 B 和抑制素 A 的受体^[1][2]。
不同物种的 ACVR2A 蛋白的氨基酸序列为非常稳定，由此得出的结论是，在进化过程中，ACVR2A 仅发生了轻微改变，并且在人类和动物中，其功能是相似的。
激活素和 BMP 的信号传导是高度混杂的，因为除了通过 ALK4/7 发出信号之外，激活素 II 型受体（ACVR2A 和 2B）还可以与多种 I 型 BMP 受体 (ALK1/2/3/6) 相互作用，后者也可以与 II 型 BMP 受体 BMPRII 形成复合物。II 型受体磷酸化并激活 I 型受体，I 型受体自身磷酸化，然后结合并激活 SMAD 转录调节因子。ACVR2A 可以与不同的 I 型受体形成复合物，向 Smad2/3 (ALK4) 或 Smad1/5/8（ALK2、ALK3、ALK6）发出信号。不同的 I 型受体竞争与 ACVR2A 结合，这种竞争提供了一种平衡激活素 A 介导的 ALK4 依赖性 Smad2/3 信号传导和 BMP 介导的 ALK2 或 ALK3 依赖性 Smad1/5/8 信号传导之间信号传导的机制。在骨髓瘤细胞中，BMP-6 和 BMP-9 通过 ACVR2A/ACVR2B/ALK2 诱导的 SMAD1/5/8 激活可被激活素 A 治疗抑制^{[1][3]< /sup>。}

Recombinant human ACVR2A (5 μg/mL) inhibits the effects of BMP-9 on INA-6 and IH-1 cells^[1].
Recombinant human ACVR2A (100 μg/mL; 96 hours) blocks the β-cell-proliferative effect of adenoviruses containing mouse Pdx-1 (AdCMV-mPdx-1) treatment^[4].

1.Measured by its ability to neutralize Activin A inhibitory effect of murine MPC-11 cells. The ED₅₀ this effect is 0.0487 μg/mL in the presence of 7.5 ng/mL Activin A, corresponding to a specific activity is 2.05×10⁴ units/mg.
2.Measured by its ability to neutralize Activin-mediated inhibition on MPC-11 cell proliferation. The ED₅₀ for this effect is 71.4 ng/mL in the presence of 10 ng/ml Recombinant Human Activin A, corresponding to a specific activity is 1.4×10⁴ units/mg.

• 
  Measured by its ability to neutralize Activin A inhibitory effect of murine MPC-11 cells. The ED₅₀ for this effect is 0.0487 μg/ml in the presence of 7.5 ng/mL Activin A, corresponding to a specific activity is 2.05×10⁴ units/mg.

Human

HEK293

C-6*His

P27037-1 (A20-P134)

92  [NCBI]

AILGRSETQECLFFNANWEKDRTNQTGVEPCYGDKDKRRHCFATWKNISGSIEIVKQGCWLDDINCYDRTDCVEKKDSPEVYFCCCEGNMCNEKFSYFPEMEVTQPTSNPVTPKPHHHHHH

Approximately 24-40 kDa due to the glycosylation.

Greater than 95% as determined by reducing SDS-PAGE

无菌粉末.

Lyophilized from a 0.22 μm filtered solution of 20 mM PB, 150 mM NaCl, 1 mM DTT, pH 7.4 or PBS, pH 7.4, 8% trehalose.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.